论文部分内容阅读
目的探究尿液亮氨酸氨基肽酶(LAP)和谷氨酰转肽酶(GGT)在筛查糖尿病患者早期肾损害中的价值,为临床实践中及时发现及治疗糖尿病早期肾损害提供科学指导。方法 30例糖尿病无肾损害患者(A组)及38例糖尿病肾损害患者(B组),另选取同期在本院进行体检的健康体检者40例作为对照组(C组)。利用速率法测定三组被试尿液LAP和GGT的活性,并对三组进行比较。结果 A组与B组被试LAP和GGT水平均显著高于C组(P<0.05),而B组患者的LAP和GGT水平又显著高于A组,差异有统计学意义(P<0.05)。结论尿液LAP和GGT的活性检测对临床上尽早发现糖尿病早期肾损害有现实价值和意义。
Objective To investigate the value of urinary leucine aminopeptidase (LAP) and glutamyl transpeptidase (GGT) in the screening of early renal damage in diabetic patients and provide scientific guidance for timely detection and treatment of early diabetic nephropathy in clinical practice . Methods Thirty diabetic patients without renal damage (group A) and 38 patients with diabetic nephropathy (group B) were enrolled in this study. Forty healthy subjects were selected as control group (group C) during the same period. The urine activity of LAP and GGT in three groups was measured by the rate method, and the three groups were compared. Results The levels of LAP and GGT in group A and group B were significantly higher than those in group C (P <0.05), while the levels of LAP and GGT in group B were significantly higher than those in group A (P <0.05) . Conclusion The detection of urinary LAP and GGT activity has practical value and significance in early detection of early diabetic renal damage in clinic.